A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (AAT) Combined with Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant

Expanded Access Protocol (EAP) for Subjects Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

Intermediate-Size Population Expanded Access Program (EAP) for cilta-cel Out‐of‐Specification (OOS) in Patients with Multiple Myeloma

Indiana University Simon Cancer Center Hematologic Malignancies Tissue Bank